NZ595046A - Compositions and methods for extended therapy with aminopyridines - Google Patents
Compositions and methods for extended therapy with aminopyridinesInfo
- Publication number
- NZ595046A NZ595046A NZ595046A NZ59504610A NZ595046A NZ 595046 A NZ595046 A NZ 595046A NZ 595046 A NZ595046 A NZ 595046A NZ 59504610 A NZ59504610 A NZ 59504610A NZ 595046 A NZ595046 A NZ 595046A
- Authority
- NZ
- New Zealand
- Prior art keywords
- aminopyridines
- compositions
- methods
- time
- extended period
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003927 aminopyridines Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical group NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229960004979 fampridine Drugs 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15167909P | 2009-02-11 | 2009-02-11 | |
| US25956309P | 2009-11-09 | 2009-11-09 | |
| US28587209P | 2009-12-11 | 2009-12-11 | |
| US28895309P | 2009-12-22 | 2009-12-22 | |
| US29925910P | 2010-01-28 | 2010-01-28 | |
| PCT/US2010/023970 WO2010093839A1 (en) | 2009-02-11 | 2010-02-11 | Compositions and methods for extended therapy with aminopyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595046A true NZ595046A (en) | 2013-10-25 |
Family
ID=42562065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595046A NZ595046A (en) | 2009-02-11 | 2010-02-11 | Compositions and methods for extended therapy with aminopyridines |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20120029035A1 (enExample) |
| JP (1) | JP2012517449A (enExample) |
| KR (3) | KR20120000560A (enExample) |
| CN (2) | CN101896182A (enExample) |
| AR (1) | AR075413A1 (enExample) |
| AU (2) | AU2010213663A1 (enExample) |
| BR (2) | BRPI1000031A2 (enExample) |
| CA (1) | CA2751581A1 (enExample) |
| CL (1) | CL2011001927A1 (enExample) |
| CO (1) | CO6440534A2 (enExample) |
| EA (1) | EA022755B1 (enExample) |
| EC (1) | ECSP11011311A (enExample) |
| IL (1) | IL214500A0 (enExample) |
| MX (1) | MX2011008485A (enExample) |
| NI (1) | NI201100155A (enExample) |
| NZ (1) | NZ595046A (enExample) |
| PE (1) | PE20120791A1 (enExample) |
| SG (2) | SG10201609184PA (enExample) |
| TN (1) | TN2011000403A1 (enExample) |
| TW (2) | TW201034665A (enExample) |
| UY (2) | UY32445A (enExample) |
| WO (2) | WO2010093839A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| US20150111930A1 (en) * | 2013-10-23 | 2015-04-23 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| TW201125562A (en) * | 2009-09-04 | 2011-08-01 | Acorda Therapeutics Inc | Sustained release fampridine treatment in patients with multiple sclerosis |
| CN102442942A (zh) * | 2010-10-08 | 2012-05-09 | 天津和美生物技术有限公司 | 4-氨基吡啶的多晶型物及其制备和应用 |
| EP2995305B1 (en) * | 2011-01-28 | 2020-03-04 | Acorda Therapeutics, Inc. | Use of potassium channel blockers to treat cerebral palsy |
| AU2013221604B2 (en) * | 2012-02-13 | 2017-11-23 | Acorda Therapeutics, Inc. | Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine |
| WO2014028387A1 (en) * | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
| CN105993016B (zh) * | 2014-02-04 | 2020-01-10 | 奥普蒂马塔公司 | 用于为具有特定疾病的个体规划医疗的计算机化系统 |
| RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
| TWI679012B (zh) * | 2015-09-11 | 2019-12-11 | 法德生技藥品股份有限公司 | 含有達方吡啶的緩釋口服滲透錠劑及其用途 |
| WO2022124946A1 (ru) * | 2020-12-10 | 2022-06-16 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение |
| CN112914884B (zh) * | 2021-01-19 | 2022-02-11 | 重庆火后草科技有限公司 | 通过稳态时长置信度测量睡眠状态下的体重值的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| US6288026B1 (en) * | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
| US8007826B2 (en) * | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) * | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
-
2010
- 2010-02-11 CN CN2010800008624A patent/CN101896182A/zh active Pending
- 2010-02-11 TW TW099104403A patent/TW201034665A/zh unknown
- 2010-02-11 BR BRPI1000031A patent/BRPI1000031A2/pt not_active Application Discontinuation
- 2010-02-11 PE PE2011001475A patent/PE20120791A1/es not_active Application Discontinuation
- 2010-02-11 AU AU2010213663A patent/AU2010213663A1/en not_active Abandoned
- 2010-02-11 NZ NZ595046A patent/NZ595046A/xx not_active IP Right Cessation
- 2010-02-11 MX MX2011008485A patent/MX2011008485A/es not_active Application Discontinuation
- 2010-02-11 UY UY0001032445A patent/UY32445A/es not_active Application Discontinuation
- 2010-02-11 UY UY0001032444A patent/UY32444A/es not_active Application Discontinuation
- 2010-02-11 CA CA2751581A patent/CA2751581A1/en not_active Abandoned
- 2010-02-11 KR KR1020117021266A patent/KR20120000560A/ko not_active Ceased
- 2010-02-11 WO PCT/US2010/023970 patent/WO2010093839A1/en not_active Ceased
- 2010-02-11 JP JP2011549357A patent/JP2012517449A/ja active Pending
- 2010-02-11 EA EA201171043A patent/EA022755B1/ru unknown
- 2010-02-11 WO PCT/US2010/023969 patent/WO2010093838A1/en not_active Ceased
- 2010-02-11 SG SG10201609184PA patent/SG10201609184PA/en unknown
- 2010-02-11 CN CN201080000861XA patent/CN102046174A/zh active Pending
- 2010-02-11 KR KR1020187029188A patent/KR20180114250A/ko not_active Ceased
- 2010-02-11 KR KR1020177007639A patent/KR20170034452A/ko not_active Ceased
- 2010-02-11 US US13/148,231 patent/US20120029035A1/en not_active Abandoned
- 2010-02-11 SG SG2011057783A patent/SG173641A1/en unknown
- 2010-02-11 TW TW099104401A patent/TW201032809A/zh unknown
- 2010-02-11 BR BRPI1000030A patent/BRPI1000030A2/pt not_active IP Right Cessation
- 2010-02-12 AR ARP100100402A patent/AR075413A1/es unknown
-
2011
- 2011-08-07 IL IL214500A patent/IL214500A0/en unknown
- 2011-08-09 NI NI201100155A patent/NI201100155A/es unknown
- 2011-08-10 CL CL2011001927A patent/CL2011001927A1/es unknown
- 2011-08-10 TN TN2011000403A patent/TN2011000403A1/fr unknown
- 2011-09-08 EC EC2011011311A patent/ECSP11011311A/es unknown
- 2011-09-09 CO CO11116663A patent/CO6440534A2/es not_active Application Discontinuation
-
2014
- 2014-11-26 US US14/555,487 patent/US20150313886A1/en not_active Abandoned
-
2016
- 2016-08-25 AU AU2016219650A patent/AU2016219650C1/en not_active Ceased
-
2017
- 2017-05-17 US US15/597,991 patent/US20170319562A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MY159353A (en) | Pirfenidone treatment for patients with atypical liver function | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| PH12013500406A1 (en) | Deuterated analogs of pridopidine useful as dopaminergic stabilizers | |
| NZ612717A (en) | Treatment of pain associated with dislocation of basal endometrium | |
| MX2021000431A (es) | Metodos y composiciones para el tratamiento de trastorno por deficit de atencion. | |
| MY160768A (en) | Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease | |
| MX2010010026A (es) | Agente para tratar enfermedad. | |
| NZ594056A (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
| NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
| JP2012517449A5 (enExample) | ||
| NZ625440A (en) | Anti-cxcr1 compositions and methods | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| NZ606964A (en) | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| GEP20166488B (en) | Co-crystals and salts of ccr3-inhibitors | |
| NZ576424A (en) | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor | |
| NZ596851A (en) | Methods of treating hepatic encephalopathy | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 FEB 2017 BY COMPUTER PACKAGES INC Effective date: 20140328 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 FEB 2018 BY COMPUTER PACKAGES INC Effective date: 20170118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 FEB 2019 BY COMPUTER PACKAGES INC Effective date: 20180118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 FEB 2020 BY COMPUTER PACKAGES INC Effective date: 20190118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 FEB 2021 BY COMPUTER PACKAGES INC Effective date: 20200118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 FEB 2022 BY COMPUTER PACKAGES INC Effective date: 20210119 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 FEB 2023 BY COMPUTER PACKAGES INC Effective date: 20220117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 FEB 2024 BY COMPUTER PACKAGES INC Effective date: 20230117 |
|
| LAPS | Patent lapsed |